IOBT News

November kicked off with a 12 IPO week and shoe brand Allbirds (BIRD) was at the front of the flock, posting a first-day pop of 93%. 23 SPACs also went public. New issuers continued to join the pipeline, with five IPOs and 13 SPACs submitting initial filings. Two issuers postponed this past week: Russian car-sharing firm Delimobil (DMOB) and...read more

IO Biotech, a Phase 3-ready biotech developing immunotherapies for melanoma and other cancers, raised $100 million by offering 7.2 million shares at $14, the low end of the range of $14 to $17. The company offered 0.7 million more shares than anticipated. IO Biotech is developing is targeting immunosuppresive mechanisms of cancer survival mediated by key immunosuppressive proteins...read more

IO Biotech, a Phase 3-ready biotech developing immunotherapies for melanoma and other cancers, announced terms for its IPO on Monday. The Copenhagen, Denmark-based company plans to raise $101 million by offering 6.5 million shares at a price range of $14 to $17. At the midpoint of the proposed range, IO Biotech would command a fully diluted market value of $405 million. IO...read more

Updated Monday, 11/1. The IPO market has seen double digit offerings for the past two weeks, and is scheduled to continue its streak, with 13 IPOs expected to raise $2.7 billion. Drug discovery company Evotec (EVO) plans to raise $576 million at a $9.2 billion market cap. The company aims to accelerate and improve the efficiency of the drug discovery...read more